2025-04-15 - Analysis Report
## Albemarle Corp (ALB) Stock Review

**0. Key Figures Summary:**

* **ALB Cumulative Return:** 2.17%
* **VOO (S&P 500) Cumulative Return:** 66.69%
* **Return Difference:** -64.5%
* **Relative Divergence:** 0.2 (Indicates ALB significantly underperformed VOO, close to its historical minimum relative performance.)
* **Current Price:** $57.39
* **Market Risk Indicator (MRI):** 0.4585 (High Risk)
* **Expected Return (Long Term):** 14365.9% (significantly higher than S&P 500)

**1. Performance Comparison & Company Overview:**

Albemarle Corp is a leading global producer of lithium, bromine, and related chemicals.  As shown above, ALB significantly underperformed the S&P 500 (VOO) over the measured period, with a cumulative return of 2.17% compared to VOO's 66.69%. The difference of -64.5% places ALB near the bottom of its historical relative performance range.  The provided alpha and beta analysis suggests high volatility and significant outperformance in certain periods (2019-2022) but considerable underperformance in recent years (2022-2025).  Note that the extremely high CAGR values in some periods and sharply negative values in others highlight a substantial degree of risk.  The high Beta values also support this conclusion.

**Alpha and Beta Analysis:**

The provided data reveals significant fluctuations in ALB's performance relative to the market.  High positive alphas indicate periods of significant outperformance, while negative alphas signify underperformance. The large swings in CAGR and MDD underscore substantial volatility.  The high Beta consistently demonstrates ALB's sensitivity to market movements.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 99.0% | 7.7% | 70.0% | 0.0 | 13.7 |
| 2016-2018  | 13.0% | 58.1% | -5.0% | 0.0 | 8.4 |
| 2017-2019  | -45.0% | 58.1% | -74.0% | -0.0 | 8.1 |
| 2018-2020  | 101.0% | 62.9% | 75.0% | 0.7 | 16.6 |
| 2019-2021  | 268.0% | 62.9% | 214.0% | 0.8 | 26.5 |
| 2020-2022  | 239.0% | 75.8% | 233.0% | 1.1 | 24.8 |
| 2021-2023  | -53.0% | 77.6% | -69.0% | 0.6 | 16.6 |
| 2022-2024  | -204.0% | 77.6% | -221.0% | 0.8 | 10.1 |
| 2023-2025  | -346.0% | 77.6% | -360.0% | 2.1 | 6.8 |


**2. Recent Price Movement:**

* **Closing Price:** $57.39
* **5-Day Moving Average:** $56.00
* **20-Day Moving Average:** $68.48
* **60-Day Moving Average:** $76.20

The price is below all three moving averages, suggesting a possible downtrend.  The recent price increase of 1.27% from the previous close might indicate a minor short-term bounce, but the longer-term trend seems bearish.


**3. Technical Indicators:**

* **RSI:** 27.92 (Suggests oversold conditions, potentially signaling a bounce, but also indicating high risk).
* **PPO:** -2.10 (Negative value confirms bearish momentum).
* **Relative Divergence (20-day):** -3.0 (Short-term downward trend).
* **Market Risk Indicator (MRI):** 0.4585 (High Risk)

The indicators paint a picture of a potentially oversold market, but with significant risk. The negative PPO and relative divergence confirm bearish momentum.  The high MRI score strengthens this bearish outlook. The recent price increase of 1.27% is relatively small given the overall downward trend.


**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue       |
|------------|-------|---------------|
| 2024-11-06 | -9.45  | $1.35 B       |
| 2024-07-31 | -1.96  | $1.43 B       |
| 2024-05-01 | -0.08  | $1.36 B       |
| 2023-11-01 | 2.58  | $2.31 B       |
| 2024-11-06 | 2.58  | $2.31 B       |

There's a clear discrepancy in the data for November 2024, showing both positive and negative EPS with the same revenue.  This needs clarification. The recent quarters show declining revenues and significant EPS losses, indicating substantial financial challenges.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $1.23B | 11.22% |
| 2024-09-30 | $1.35B | -7.68% |
| 2024-06-30 | $1.43B | -0.74% |
| 2024-03-31 | $1.36B | 2.86% |
| 2023-12-31 | $2.36B | -29.88% |

Revenue is declining, and profit margins are highly volatile, swinging from positive to significantly negative.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $9.96B | 0.76% |
| 2024-09-30 | $10.24B | -10.44% |
| 2024-06-30 | $11.22B | -1.68% |
| 2024-03-31 | $11.53B | 0.02% |
| 2023-12-31 | $9.41B | -6.56% |

Equity fluctuates, and ROE is mostly negative, reflecting the company's recent financial struggles.


**6. Overall Analysis:**

ALB is currently experiencing significant financial difficulties, as evidenced by declining revenues, volatile and largely negative profit margins, negative EPS, and a high level of risk as indicated by the MRI. While the RSI suggests oversold conditions, and the extremely high projected long-term return is intriguing, the underlying negative trends in financial performance and the persistent underperformance compared to the S&P 500 raise serious concerns. The extremely high volatility and associated high risk would necessitate an extremely high risk tolerance to consider an investment in ALB.  Further investigation into the conflicting November 2024 earnings data is crucial.  The high projected long-term return should be viewed with extreme skepticism given the current financial situation and its recent history of wildly fluctuating performance.
